{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T02:38:07Z","timestamp":1791945487435,"version":"4.3.4"},"reference-count":86,"publisher":"Springer Science and Business Media LLC","issue":"12","license":[{"start":{"date-parts":[[2019,6,10]],"date-time":"2019-06-10T00:00:00Z","timestamp":1560124800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2019,6,10]],"date-time":"2019-06-10T00:00:00Z","timestamp":1560124800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"funder":[{"name":"Department of Veterans Affairs, Veterans Health Administration, Office of Research and Development, Quality Enhancement Research Initiative","award":["NA"],"award-info":[{"award-number":["NA"]}]},{"name":"AHRQ PCOR K12","award":["K12HS022981"],"award-info":[{"award-number":["K12HS022981"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J GEN INTERN MED"],"published-print":{"date-parts":[[2019,12]]},"DOI":"10.1007\/s11606-019-05074-8","type":"journal-article","created":{"date-parts":[[2019,6,10]],"date-time":"2019-06-10T14:10:49Z","timestamp":1560175849000},"page":"2858-2873","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":146,"title":["Pharmacotherapy for Cocaine Use Disorder\u2014a Systematic Review and Meta-analysis"],"prefix":"10.1007","volume":"34","author":[{"given":"Brian","family":"Chan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karli","family":"Kondo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michele","family":"Freeman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chelsea","family":"Ayers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jessica","family":"Montgomery","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Devan","family":"Kansagara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,6,10]]},"reference":[{"key":"5074_CR1","volume-title":"Trends in substance use disorders among adults aged 18 or older. The CBHSQ Report","author":"RN Lipari","year":"2017","unstructured":"Lipari RN, Van Horn SL. Trends in substance use disorders among adults aged 18 or older. The CBHSQ Report, 2017. Center for Behavioral Health Statistics and Quality, Substance Abuse and Mental Health Services Administration, Rockville."},{"issue":"1","key":"5074_CR2","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1053\/j.semdp.2008.12.001","volume":"26","author":"RA Goldstein","year":"2009","unstructured":"Goldstein RA, DesLauriers C, Burda A, Johnson-Arbor K. Cocaine: history, social implications, and toxicity: a review. Semin Diagn Pathol 2009;26(1):10\u20137.","journal-title":"Semin Diagn Pathol"},{"issue":"33","key":"5074_CR3","doi-asserted-by":"publisher","first-page":"5624","DOI":"10.2174\/092986712803988893","volume":"19","author":"I Riezzo","year":"2012","unstructured":"Riezzo I, Fiore C, De Carlo D, Pascale N, Neri M, Turillazzi E, et al. Side effects of cocaine abuse: multiorgan toxicity and pathological consequences. Curr Med Chem 2012;19(33):5624\u201346.","journal-title":"Curr Med Chem"},{"key":"5074_CR4","doi-asserted-by":"publisher","unstructured":"Pani PP, Trogu E, Vacca R, Amato L, Vecchi S, Davoli M. Disulfiram for the treatment of cocaine dependence. Cochrane Database Syst Rev 2010(1):CD007024. doi: \nhttps:\/\/doi.org\/10.1002\/14651858.CD007024.pub2\n\n.","DOI":"10.1002\/14651858.CD007024.pub2"},{"key":"5074_CR5","doi-asserted-by":"publisher","unstructured":"Minozzi S, Cinquini M, Amato L, Davoli M, Farrell MF, Pani PP, et al. Anticonvulsants for cocaine dependence. Cochrane Database Syst Rev 2015(4):CD006754. doi: \nhttps:\/\/doi.org\/10.1002\/14651858.CD006754.pub4\n\n.","DOI":"10.1002\/14651858.CD006754.pub4"},{"key":"5074_CR6","doi-asserted-by":"publisher","unstructured":"Minozzi S, Amato L, Pani PP, Solimini R, Vecchi S, De Crescenzo F, et al. Dopamine agonists for the treatment of cocaine dependence. Cochrane Database Syst Rev 2015(5):CD003352. doi: \nhttps:\/\/doi.org\/10.1002\/14651858.CD003352.pub4\n\n.","DOI":"10.1002\/14651858.CD003352.pub4"},{"key":"5074_CR7","doi-asserted-by":"publisher","unstructured":"Castells X, Cunill R, Perez-Mana C, Vidal X, Capella D. Psychostimulant drugs for cocaine dependence. Cochrane Database Syst Rev 2016;9:CD007380. doi: \nhttps:\/\/doi.org\/10.1002\/14651858.CD007380.pub4\n\n.","DOI":"10.1002\/14651858.CD007380.pub4"},{"key":"5074_CR8","doi-asserted-by":"publisher","unstructured":"Indave BI, Minozzi S, Pani PP, Amato L. Antipsychotic medications for cocaine dependence. Cochrane Database Syst Rev 2016;3:CD006306. doi: \nhttps:\/\/doi.org\/10.1002\/14651858.CD006306.pub3\n\n.","DOI":"10.1002\/14651858.CD006306.pub3"},{"issue":"6","key":"5074_CR9","doi-asserted-by":"publisher","first-page":"e1000097","DOI":"10.1371\/journal.pmed1000097","volume":"6","author":"D Moher","year":"2009","unstructured":"Moher D, Liberati A, Tetzlaff J, Altman DG, The PRISMA Group (2009). Preferred Reporting Items for Systematic Reviews and Meta-Analyses: The PRISMA Statement. PLoS Med 6(6): e1000097. doi:\nhttps:\/\/doi.org\/10.1371\/journal.pmed1000097\n\n. Available from: www.prisma-statement.org.","journal-title":"PLoS Med"},{"key":"5074_CR10","unstructured":"Higgins J, Green S. Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0. 2011 [cited 2017 March 24]. Available from: \nhttp:\/\/handbook.cochrane.org\/\n\n."},{"key":"5074_CR11","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.drugalcdep.2015.11.004","volume":"158","author":"BD Kiluk","year":"2016","unstructured":"Kiluk BD, Carroll KM, Duhig A, Falk DE, Kampman K, Lai S, et al. Measures of outcome for stimulant trials: ACTTION recommendations and research agenda. Drug Alcohol Depend 2016;158:1\u20137. doi: \nhttps:\/\/doi.org\/10.1016\/j.drugalcdep.2015.11.004\n\n.","journal-title":"Drug Alcohol Depend"},{"issue":"3","key":"5074_CR12","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1016\/0197-2456(86)90046-2","volume":"7","author":"R DerSimonian","year":"1986","unstructured":"DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials 1986;7(3):177\u201388.","journal-title":"Control Clin Trials"},{"key":"5074_CR13","unstructured":"Review Manager (RevMan) [Computer program]. Version 5.3. Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration, 2014."},{"issue":"11","key":"5074_CR14","doi-asserted-by":"publisher","first-page":"1539","DOI":"10.1002\/sim.1186","volume":"21","author":"JP Higgins","year":"2002","unstructured":"Higgins JP, Thompson SG. Quantifying heterogeneity in a meta-analysis. Stat Med 2002;21(11):1539\u201358. doi: \nhttps:\/\/doi.org\/10.1002\/sim.1186\n\n.","journal-title":"Stat Med"},{"issue":"7414","key":"5074_CR15","doi-asserted-by":"publisher","first-page":"557","DOI":"10.1136\/bmj.327.7414.557","volume":"327","author":"JP Higgins","year":"2003","unstructured":"Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. BMJ 2003;327(7414):557\u201360. doi: \nhttps:\/\/doi.org\/10.1136\/bmj.327.7414.557\n\n.","journal-title":"BMJ"},{"key":"5074_CR16","volume-title":"Grading the Strength of a Body of Evidence When Assessing Health Care Interventions for the Effective Health Care Program of the Agency for Healthcare Research and Quality: An Update","author":"N Berkman","year":"2013","unstructured":"Berkman N, Lohr K, Ansari M, McDonagh M, Balk E, Whitlock E, et al. Grading the Strength of a Body of Evidence When Assessing Health Care Interventions for the Effective Health Care Program of the Agency for Healthcare Research and Quality: An Update. Rockville: Agency for Healthcare Research and Quality; Methods Guide for Comparative Effectiveness Reviews (AHRQ Publication No. 13(14)-EHC130-EF), 2013."},{"key":"5074_CR17","doi-asserted-by":"publisher","unstructured":"Pani PP, Trogu E, Vecchi S, Amato L. Antidepressants for cocaine dependence and problematic cocaine use. Cochrane Database Syst Rev. 2011(12):CD002950. doi: \nhttps:\/\/doi.org\/10.1002\/14651858.CD002950.pub3\n\n.","DOI":"10.1002\/14651858.CD002950.pub3"},{"issue":"1","key":"5074_CR18","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1111\/j.1521-0391.2013.12065.x.","volume":"23","author":"WN Raby","year":"2014","unstructured":"Raby WN, Rubin EA, Garawi F, Cheng W, Mason E, Sanfilippo L, et al. A randomized, double-blind, placebo-controlled trial of venlafaxine for the treatment of depressed cocaine-dependent patients. Am J Addict 2014;23(1):68\u201375. doi: \nhttps:\/\/doi.org\/10.1111\/j.1521-0391.2013.12065.x.","journal-title":"Am J Addict"},{"issue":"2","key":"5074_CR19","doi-asserted-by":"publisher","first-page":"181","DOI":"10.3109\/00952990.2011.644002.","volume":"38","author":"M Afshar","year":"2012","unstructured":"Afshar M, Knapp CM, Sarid-Segal O, Devine E, Colaneri LS, Tozier L, et al. The efficacy of mirtazapine in the treatment of cocaine dependence with comorbid depression. Am J Drug Alcohol Abuse 2012;38(2):181\u20136. doi: \nhttps:\/\/doi.org\/10.3109\/00952990.2011.644002.","journal-title":"Am J Drug Alcohol Abuse"},{"issue":"2","key":"5074_CR20","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1097\/JCP.0000000000000062.","volume":"34","author":"MJ Mancino","year":"2014","unstructured":"Mancino MJ, McGaugh J, Chopra MP, Guise JB, Cargile C, Williams DK, et al. Clinical efficacy of sertraline alone and augmented with gabapentin in recently abstinent cocaine-dependent patients with depressive symptoms. J Clin Psychopharmacol 2014;34(2):234\u20139. doi: \nhttps:\/\/doi.org\/10.1097\/JCP.0000000000000062.","journal-title":"J Clin Psychopharmacol"},{"issue":"1","key":"5074_CR21","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1111\/j.1360-0443.2011.03552.x.","volume":"107","author":"A Oliveto","year":"2012","unstructured":"Oliveto A, Poling J, Mancino MJ, Williams DK, Thostenson J, Pruzinsky R, et al. Sertraline delays relapse in recently abstinent cocaine-dependent patients with depressive symptoms. Addiction 2012;107(1):131\u201341. doi: \nhttps:\/\/doi.org\/10.1111\/j.1360-0443.2011.03552.x.","journal-title":"Addiction"},{"issue":"1","key":"5074_CR22","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1097\/FBP.0000000000000268","volume":"28","author":"LM Moran","year":"2017","unstructured":"Moran LM, Phillips KA, Kowalczyk WJ, Ghitza UE, Agage DA, Epstein DH, et al. Aripiprazole for cocaine abstinence: a randomized-controlled trial with ecological momentary assessment. Behav Pharmacol 2017;28(1):63\u201373. doi: \nhttps:\/\/doi.org\/10.1097\/FBP.0000000000000268\n\n.","journal-title":"Behav Pharmacol"},{"issue":"2","key":"5074_CR23","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1001\/archpsyc.63.2.219.","volume":"63","author":"J Poling","year":"2006","unstructured":"Poling J, Oliveto A, Petry N, Sofuoglu M, Gonsai K, Gonzalez G, et al. Six-month trial of bupropion with contingency management for cocaine dependence in a methadone-maintained population. Arch Gen Psychiatry 2006;63(2):219\u201328. doi: \nhttps:\/\/doi.org\/10.1001\/archpsyc.63.2.219.","journal-title":"Arch Gen Psychiatry"},{"issue":"1\u20132","key":"5074_CR24","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1016\/j.drugalcdep.2010.04.006.","volume":"111","author":"A Bisaga","year":"2010","unstructured":"Bisaga A, Aharonovich E, Cheng WY, Levin FR, Mariani JJ, Raby WN, et al. A placebo-controlled trial of memantine for cocaine dependence with high-value voucher incentives during a pre-randomization lead-in period. Drug Alcohol Depend 2010;111(1\u20132):97\u2013104. doi: \nhttps:\/\/doi.org\/10.1016\/j.drugalcdep.2010.04.006.","journal-title":"Drug Alcohol Depend"},{"issue":"1\u20133","key":"5074_CR25","doi-asserted-by":"publisher","first-page":"150","DOI":"10.1016\/j.drugalcdep.2012.10.024.","volume":"130","author":"SL Walsh","year":"2013","unstructured":"Walsh SL, Middleton LS, Wong CJ, Nuzzo PA, Campbell CL, Rush CR, et al. Atomoxetine does not alter cocaine use in cocaine dependent individuals: double blind randomized trial. Drug Alcohol Depend 2013;130(1\u20133):150\u20137. doi: \nhttps:\/\/doi.org\/10.1016\/j.drugalcdep.2012.10.024.","journal-title":"Drug Alcohol Depend"},{"issue":"7","key":"5074_CR26","doi-asserted-by":"publisher","first-page":"757","DOI":"10.4088\/JCP.13m08862.","volume":"75","author":"TM Winhusen","year":"2014","unstructured":"Winhusen TM, Kropp F, Lindblad R, Douaihy A, Haynes L, Hodgkins C, et al. Multisite, randomized, double-blind, placebo-controlled pilot clinical trial to evaluate the efficacy of buspirone as a relapse-prevention treatment for cocaine dependence. J Clin Psychiatry 2014;75(7):757\u201364. doi: \nhttps:\/\/doi.org\/10.4088\/JCP.13m08862.","journal-title":"J Clin Psychiatry"},{"issue":"12","key":"5074_CR27","doi-asserted-by":"publisher","first-page":"1440","DOI":"10.4088\/JCP.v64n1207","volume":"64","author":"S Shoptaw","year":"2003","unstructured":"Shoptaw S, Yang X, Rotheram-Fuller EJ, Hsieh Y-CM, Kintaudi PC, Charuvastra VC, et al. Randomized placebo-controlled trial of baclofen for cocaine dependence: preliminary effects for individuals with chronic patterns of cocaine use. J Clin Psychiatry 2003;64(12):1440\u20138.","journal-title":"J Clin Psychiatry"},{"issue":"1\u20132","key":"5074_CR28","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1016\/j.drugalcdep.2009.03.011.","volume":"103","author":"R Kahn","year":"2009","unstructured":"Kahn R, Biswas K, Childress A-R, Shoptaw S, Fudala PJ, Gorgon L, et al. Multi-center trial of baclofen for abstinence initiation in severe cocaine-dependent individuals. Drug Alcohol Depend 2009;103(1\u20132):59\u201364. doi: \nhttps:\/\/doi.org\/10.1016\/j.drugalcdep.2009.03.011.","journal-title":"Drug Alcohol Depend"},{"issue":"3","key":"5074_CR29","doi-asserted-by":"publisher","first-page":"398","DOI":"10.4088\/JCP.14m09377","volume":"77","author":"L Baldacara","year":"2016","unstructured":"Baldacara L, Cogo-Moreira H, Parreira BL, Diniz TA, Milhomem JJ, Fernandes CC, et al. Efficacy of topiramate in the treatment of crack cocaine dependence: a double-blind, randomized, placebo-controlled trial. J Clin Psychiatry 2016;77(3):398\u2013406. doi: \nhttps:\/\/doi.org\/10.4088\/JCP.14m09377","journal-title":"J Clin Psychiatry"},{"issue":"12","key":"5074_CR30","doi-asserted-by":"publisher","first-page":"1338","DOI":"10.1001\/jamapsychiatry.2013.2295","volume":"70","author":"BA Johnson","year":"2013","unstructured":"Johnson BA, Ait-Daoud N, Wang X-Q, Penberthy JK, Javors MA, Seneviratne C, et al. Topiramate for the treatment of cocaine addiction: a randomized clinical trial. JAMA Psychiatry 2013;70(12):1338\u201346. doi: \nhttps:\/\/doi.org\/10.1001\/jamapsychiatry.2013.2295","journal-title":"JAMA Psychiatry"},{"issue":"3","key":"5074_CR31","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1016\/j.drugalcdep.2004.03.008","volume":"75","author":"KM Kampman","year":"2004","unstructured":"Kampman KM, Pettinati H, Lynch KG, Dackis C, Sparkman T, Weigley C, et al. A pilot trial of topiramate for the treatment of cocaine dependence. Drug Alcohol Depend 2004;75(3):233\u201340. doi: \nhttps:\/\/doi.org\/10.1016\/j.drugalcdep.2004.03.008","journal-title":"Drug Alcohol Depend"},{"issue":"1","key":"5074_CR32","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1016\/j.drugalcdep.2013.05.026","volume":"133","author":"KM Kampman","year":"2013","unstructured":"Kampman KM, Pettinati HM, Lynch KG, Spratt K, Wierzbicki MR, O\u2019Brien CP. A double-blind, placebo-controlled trial of topiramate for the treatment of comorbid cocaine and alcohol dependence. Drug Alcohol Depend 2013;133(1):94\u20139. doi: \nhttps:\/\/doi.org\/10.1016\/j.drugalcdep.2013.05.026","journal-title":"Drug Alcohol Depend"},{"key":"5074_CR33","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1016\/j.drugalcdep.2014.02.024","volume":"138","author":"M Nuijten","year":"2014","unstructured":"Nuijten M, Blanken P, van den Brink W, Hendriks V. Treatment of crack-cocaine dependence with topiramate: a randomized controlled feasibility trial in The Netherlands. Drug Alcohol Depend 2014;138:177\u201384. doi: \nhttps:\/\/doi.org\/10.1016\/j.drugalcdep.2014.02.024","journal-title":"Drug Alcohol Depend"},{"key":"5074_CR34","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1016\/j.drugalcdep.2014.03.033","volume":"140","author":"A Umbricht","year":"2014","unstructured":"Umbricht A, DeFulio A, Winstanley EL, Tompkins DA, Peirce J, Mintzer MZ, et al. Topiramate for cocaine dependence during methadone maintenance treatment: a randomized controlled trial. Drug Alcohol Depend 2014;140:92\u2013100. doi: \nhttps:\/\/doi.org\/10.1016\/j.drugalcdep.2014.03.033","journal-title":"Drug Alcohol Depend"},{"issue":"8","key":"5074_CR35","doi-asserted-by":"publisher","first-page":"713","DOI":"10.1001\/archpsyc.1997.01830200041006","volume":"54","author":"RS Schottenfeld","year":"1997","unstructured":"Schottenfeld RS, Pakes JR, Oliveto A, Ziedonis D, Kosten TR. Buprenorphine vs methadone maintenance treatment for concurrent opioid dependence and cocaine abuse. Arch Gen Psychiatry 1997;54(8):713\u201320.","journal-title":"Arch Gen Psychiatry"},{"issue":"2","key":"5074_CR36","doi-asserted-by":"publisher","first-page":"340","DOI":"10.1176\/appi.ajp.162.2.340","volume":"162","author":"RS Schottenfeld","year":"2005","unstructured":"Schottenfeld RS, Chawarski MC, Pakes JR, Pantalon MV, Carroll KM, Kosten TR. Methadone versus buprenorphine with contingency management or performance feedback for cocaine and opioid dependence. Am J Psychiatry 2005;162(2):340\u20139. doi: \nhttps:\/\/doi.org\/10.1176\/appi.ajp.162.2.340","journal-title":"Am J Psychiatry"},{"key":"5074_CR37","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1016\/j.drugalcdep.2015.12.036","volume":"160","author":"KM Carroll","year":"2016","unstructured":"Carroll KM, Nich C, Petry NM, Eagan DA, Shi JM, Ball SA. A randomized factorial trial of disulfiram and contingency management to enhance cognitive behavioral therapy for cocaine dependence. Drug Alcohol Depend 2016;160:135\u201342. doi: \nhttps:\/\/doi.org\/10.1016\/j.drugalcdep.2015.12.036","journal-title":"Drug Alcohol Depend"},{"issue":"1\u20132","key":"5074_CR38","doi-asserted-by":"publisher","first-page":"224","DOI":"10.1016\/j.drugalcdep.2012.05.019","volume":"126","author":"KM Carroll","year":"2012","unstructured":"Carroll KM, Nich C, Shi JM, Eagan D, Ball SA. Efficacy of disulfiram and Twelve Step Facilitation in cocaine-dependent individuals maintained on methadone: a randomized placebo-controlled trial. Drug Alcohol Depend 2012;126(1\u20132):224\u201331. doi: \nhttps:\/\/doi.org\/10.1016\/j.drugalcdep.2012.05.019","journal-title":"Drug Alcohol Depend"},{"issue":"3","key":"5074_CR39","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1016\/j.biopsych.2012.07.011","volume":"73","author":"TR Kosten","year":"2013","unstructured":"Kosten TR, Wu G, Huang W, Harding MJ, Hamon SC, Lappalainen J, et al. Pharmacogenetic randomized trial for cocaine abuse: disulfiram and dopamine beta-hydroxylase. Biol Psychiatry 2013;73(3):219\u201324. doi: \nhttps:\/\/doi.org\/10.1016\/j.biopsych.2012.07.011","journal-title":"Biol Psychiatry"},{"issue":"2\u20133","key":"5074_CR40","doi-asserted-by":"publisher","first-page":"184","DOI":"10.1016\/j.drugalcdep.2010.07.022","volume":"113","author":"A Oliveto","year":"2011","unstructured":"Oliveto A, Poling J, Mancino MJ, Feldman Z, Cubells JF, Pruzinsky R, et al. Randomized, double blind, placebo-controlled trial of disulfiram for the treatment of cocaine dependence in methadone-stabilized patients. Drug Alcohol Depend 2011;113(2\u20133):184\u201391. doi: \nhttps:\/\/doi.org\/10.1016\/j.drugalcdep.2010.07.022","journal-title":"Drug Alcohol Depend"},{"key":"5074_CR41","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1016\/j.drugalcdep.2013.12.007","volume":"136","author":"RS Schottenfeld","year":"2014","unstructured":"Schottenfeld RS, Chawarski MC, Cubells JF, George TP, Lappalainen J, Kosten TR. Randomized clinical trial of disulfiram for cocaine dependence or abuse during buprenorphine treatment. Drug Alcohol Depend 2014;136:36\u201342. doi: \nhttps:\/\/doi.org\/10.1016\/j.drugalcdep.2013.12.007\n\n.","journal-title":"Drug Alcohol Depend"},{"issue":"11","key":"5074_CR42","doi-asserted-by":"publisher","first-page":"1401","DOI":"10.1016\/j.euroneuro.2013.05.014","volume":"23","author":"D Shorter","year":"2013","unstructured":"Shorter D, Nielsen DA, Huang W, Harding MJ, Hamon SC, Kosten TR. Pharmacogenetic randomized trial for cocaine abuse: disulfiram and alpha1A-adrenoceptor gene variation. Eur Neuropsychopharmacol 2013;23(11):1401\u20137. doi: \nhttps:\/\/doi.org\/10.1016\/j.euroneuro.2013.05.014","journal-title":"Eur Neuropsychopharmacol"},{"issue":"6","key":"5074_CR43","doi-asserted-by":"publisher","first-page":"591","DOI":"10.1111\/j.1521-0391.2014.12146.x","volume":"23","author":"HM Pettinati","year":"2014","unstructured":"Pettinati HM, Kampman KM, Lynch KG, Dundon WD, Mahoney EM, Wierzbicki MR, et al. A pilot trial of injectable, extended-release naltrexone for the treatment of co-occurring cocaine and alcohol dependence. Am J Addict 2014;23(6):591\u20137. doi: \nhttps:\/\/doi.org\/10.1111\/j.1521-0391.2014.12146.x","journal-title":"Am J Addict"},{"issue":"5","key":"5074_CR44","doi-asserted-by":"publisher","first-page":"356","DOI":"10.3109\/10550490903077929","volume":"18","author":"JM Schmitz","year":"2009","unstructured":"Schmitz JM, Lindsay JA, Green CE, Herin DV, Stotts AL, Moeller FG. High-dose naltrexone therapy for cocaine-alcohol dependence. Am J Addict 2009;18(5):356\u201362. doi: \nhttps:\/\/doi.org\/10.3109\/10550490903077929","journal-title":"Am J Addict"},{"issue":"4","key":"5074_CR45","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1080\/10550490490480982","volume":"13","author":"JM Schmitz","year":"2004","unstructured":"Schmitz JM, Stotts AL, Sayre SL, DeLaune KA, Grabowski J. Treatment of cocaine-alcohol dependence with naltrexone and relapse prevention therapy. Am J Addict 2004;13(4):333\u201341. doi: \nhttps:\/\/doi.org\/10.1080\/10550490490480982","journal-title":"Am J Addict"},{"issue":"2","key":"5074_CR46","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1016\/S0306-4603(00)00098-8","volume":"26","author":"JM Schmitz","year":"2001","unstructured":"Schmitz JM, Stotts AL, Rhoades HM, Grabowski J. Naltrexone and relapse prevention treatment for cocaine-dependent patients. Addict Behav 2001;26(2):167\u201380.","journal-title":"Addict Behav"},{"issue":"1\u20132","key":"5074_CR47","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1007\/s002130050688","volume":"139","author":"D Hersh","year":"1998","unstructured":"Hersh D, Van Kirk JR, Kranzler HR. Naltrexone treatment of comorbid alcohol and cocaine use disorders. Psychopharmacology. 1998;139(1\u20132):44\u201352.","journal-title":"Psychopharmacology."},{"issue":"4","key":"5074_CR48","doi-asserted-by":"publisher","first-page":"378","DOI":"10.1016\/j.jsat.2007.05.011","volume":"34","author":"HM Pettinati","year":"2008","unstructured":"Pettinati HM, Kampman KM, Lynch KG, Suh JJ, Dackis CA, Oslin DW, et al. Gender differences with high-dose naltrexone in patients with co-occurring cocaine and alcohol dependence. J Subst Abus Treat 2008;34(4):378\u201390. doi: \nhttps:\/\/doi.org\/10.1016\/j.jsat.2007.05.011","journal-title":"J Subst Abus Treat"},{"issue":"8","key":"5074_CR49","doi-asserted-by":"publisher","first-page":"1416","DOI":"10.1111\/add.13375","volume":"111","author":"W Ling","year":"2016","unstructured":"Ling W, Hillhouse MP, Saxon AJ, Mooney LJ, Thomas CM, Ang A, et al. Buprenorphine + naloxone plus naltrexone for the treatment of cocaine dependence: the Cocaine Use Reduction with Buprenorphine (CURB) study. Addiction 2016;111(8):1416\u201327. doi: \nhttps:\/\/doi.org\/10.1111\/add.13375","journal-title":"Addiction"},{"issue":"3","key":"5074_CR50","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1016\/j.addbeh.2010.11.003","volume":"36","author":"KM Kampman","year":"2011","unstructured":"Kampman KM, Dackis C, Pettinati HM, Lynch KG, Sparkman T, O\u2019Brien CP. A double-blind, placebo-controlled pilot trial of acamprosate for the treatment of cocaine dependence. Addict Behav 2011;36(3):217\u201321. doi: \nhttps:\/\/doi.org\/10.1016\/j.addbeh.2010.11.003","journal-title":"Addict Behav"},{"issue":"5","key":"5074_CR51","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1111\/j.1521-0391.2010.00066.x","volume":"19","author":"J Poling","year":"2010","unstructured":"Poling J, Rounsaville B, Gonsai K, Severino K, Sofuoglu M. The safety and efficacy of varenicline in cocaine using smokers maintained on methadone: a pilot study. Am J Addict 2010;19(5):401\u20138. doi: \nhttps:\/\/doi.org\/10.1111\/j.1521-0391.2010.00066.x","journal-title":"Am J Addict"},{"issue":"1\u20132","key":"5074_CR52","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1016\/j.drugalcdep.2011.08.025","volume":"121","author":"JG Plebani","year":"2012","unstructured":"Plebani JG, Lynch KG, Yu Q, Pettinati HM, O\u2019Brien CP, Kampman KM. Results of an initial clinical trial of varenicline for the treatment of cocaine dependence. Drug Alcohol Depend 2012;121(1\u20132):163\u20136. doi: \nhttps:\/\/doi.org\/10.1016\/j.drugalcdep.2011.08.025","journal-title":"Drug Alcohol Depend"},{"issue":"2","key":"5074_CR53","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1016\/j.jsat.2004.12.006","volume":"28","author":"R Malcolm","year":"2005","unstructured":"Malcolm R, LaRowe S, Cochran K, Moak D, Herron J, Brady K, et al. A controlled trial of amlodipine for cocaine dependence: a negative report. J Subst Abus Treat 2005;28(2):197\u2013204. doi: \nhttps:\/\/doi.org\/10.1016\/j.jsat.2004.12.006","journal-title":"J Subst Abus Treat"},{"key":"5074_CR54","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1016\/j.jsat.2016.11.005","volume":"73","author":"M Sofuoglu","year":"2017","unstructured":"Sofuoglu M, Poling J, Babuscio T, Gonsai K, Severino K, Nich C, et al. Carvedilol does not reduce cocaine use in methadone-maintained cocaine users. J Subst Abus Treat 2017;73:63\u20139. doi: \nhttps:\/\/doi.org\/10.1016\/j.jsat.2016.11.005","journal-title":"J Subst Abus Treat"},{"issue":"Suppl 1","key":"5074_CR55","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1111\/j.1360-0443.2005.00989.x","volume":"100","author":"MS Reid","year":"2005","unstructured":"Reid MS, Angrist B, Baker S, Woo C, Schwartz M, Montgomery A, et al. A placebo-controlled screening trial of celecoxib for the treatment of cocaine dependence. Addiction 2005;100 Suppl 1:32\u201342. doi: \nhttps:\/\/doi.org\/10.1111\/j.1360-0443.2005.00989.x\n\n.","journal-title":"Addiction"},{"issue":"1","key":"5074_CR56","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1097\/ADM.0b013e3181d80c93","volume":"5","author":"SC Licata","year":"2011","unstructured":"Licata SC, Penetar DM, Ravichandran C, Rodolico J, Palmer C, Berko J, et al. Effects of daily treatment with citicoline: a double-blind, placebo-controlled study in cocaine-dependent volunteers. J Addict Med 2011;5(1):57\u201364. doi: \nhttps:\/\/doi.org\/10.1097\/ADM.0b013e3181d80c93","journal-title":"J Addict Med"},{"issue":"8","key":"5074_CR57","doi-asserted-by":"publisher","first-page":"900","DOI":"10.1016\/j.addbeh.2012.03.008","volume":"37","author":"AP Kennedy","year":"2012","unstructured":"Kennedy AP, Gross RE, Whitfield N, Drexler KPG, Kilts CD. A controlled trial of the adjunct use of D-cycloserine to facilitate cognitive behavioral therapy outcomes in a cocaine-dependent population. Addict Behav 2012;37(8):900\u20137. doi: \nhttps:\/\/doi.org\/10.1016\/j.addbeh.2012.03.008","journal-title":"Addict Behav"},{"issue":"2","key":"5074_CR58","doi-asserted-by":"publisher","first-page":"126","DOI":"10.1037\/1064-1297.12.2.126","volume":"12","author":"S Shoptaw","year":"2004","unstructured":"Shoptaw S, Majewska MD, Wilkins J, Twitchell G, Yang X, Ling W. Participants receiving dehydroepiandrosterone during treatment for cocaine dependence show high rates of cocaine use in a placebo-controlled pilot study. Exp Clin Psychopharmacol 2004;12(2):126\u201335. doi: \nhttps:\/\/doi.org\/10.1037\/1064-1297.12.2.126","journal-title":"Exp Clin Psychopharmacol"},{"issue":"1\u20132","key":"5074_CR59","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1016\/j.drugalcdep.2012.11.021","volume":"131","author":"D Shorter","year":"2013","unstructured":"Shorter D, Lindsay JA, Kosten TR. The alpha-1 adrenergic antagonist doxazosin for treatment of cocaine dependence: A pilot study. Drug Alcohol Depend 2013;131(1\u20132):66\u201370. doi: \nhttps:\/\/doi.org\/10.1016\/j.drugalcdep.2012.11.021","journal-title":"Drug Alcohol Depend"},{"issue":"3","key":"5074_CR60","doi-asserted-by":"publisher","first-page":"302","DOI":"10.1111\/j.1521-0391.2011.00130.x","volume":"20","author":"M Sofuoglu","year":"2011","unstructured":"Sofuoglu M, Carroll KM. Effects of galantamine on cocaine use in chronic cocaine users. Am J Addict 2011;20(3):302\u20133. doi: \nhttps:\/\/doi.org\/10.1111\/j.1521-0391.2011.00130.x","journal-title":"Am J Addict"},{"issue":"2","key":"5074_CR61","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1300\/J069v22n02_04","volume":"22","author":"A Margolin","year":"2003","unstructured":"Margolin A, Kantak K, Copenhaver M, Avants SK. A preliminary, controlled investigation of magnesium L-aspartate hydrochloride for illicit cocaine and opiate use in methadone-maintained patients. J Addict Dis 2003;22(2):49\u201361. doi: \nhttps:\/\/doi.org\/10.1300\/J069v22n02_04","journal-title":"J Addict Dis"},{"issue":"2","key":"5074_CR62","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1300\/J465v26n02_02","volume":"26","author":"MS Reid","year":"2005","unstructured":"Reid MS, Angrist B, Baker SA, O\u2019Leary S, Stone J, Schwartz M, et al. A placebo controlled, double-blind study of mecamylamine treatment for cocaine dependence in patients enrolled in an opiate replacement program. Subst Abus 2005;26(2):5\u201314.","journal-title":"Subst Abus"},{"issue":"7","key":"5074_CR63","doi-asserted-by":"publisher","first-page":"973","DOI":"10.1177\/0269881111430745","volume":"26","author":"AS Kablinger","year":"2012","unstructured":"Kablinger AS, Lindner MA, Casso S, Hefti F, DeMuth G, Fox BS, et al. Effects of the combination of metyrapone and oxazepam on cocaine craving and cocaine taking: a double-blind, randomized, placebo-controlled pilot study. J Psychopharmacol 2012;26(7):973\u201381. doi: \nhttps:\/\/doi.org\/10.1177\/0269881111430745","journal-title":"J Psychopharmacol"},{"issue":"11","key":"5074_CR64","doi-asserted-by":"publisher","first-page":"950","DOI":"10.1016\/j.biopsych.2012.05.032","volume":"72","author":"JJ Mariani","year":"2012","unstructured":"Mariani JJ, Pavlicova M, Bisaga A, Nunes EV, Brooks DJ, Levin FR. Extended-release mixed amphetamine salts and topiramate for cocaine dependence: a randomized controlled trial. Biol Psychiatry 2012;72(11):950\u20136. doi: \nhttps:\/\/doi.org\/10.1016\/j.biopsych.2012.05.032","journal-title":"Biol Psychiatry"},{"issue":"5","key":"5074_CR65","doi-asserted-by":"publisher","first-page":"443","DOI":"10.1111\/j.1521-0391.2013.12034.x","volume":"22","author":"SD LaRowe","year":"2013","unstructured":"LaRowe SD, Kalivas PW, Nicholas JS, Randall PK, Mardikian PN, Malcolm RJ. A double-blind placebo-controlled trial of N-acetylcysteine in the treatment of cocaine dependence. Am J Addict 2013;22(5):443\u201352. doi: \nhttps:\/\/doi.org\/10.1111\/j.1521-0391.2013.12034.x","journal-title":"Am J Addict"},{"issue":"3","key":"5074_CR66","doi-asserted-by":"publisher","first-page":"256","DOI":"10.1016\/j.drugalcdep.2006.02.011","volume":"84","author":"BA Johnson","year":"2006","unstructured":"Johnson BA, Roache JD, Ait-Daoud N, Javors MA, Harrison JM, Elkashef A, et al. A preliminary randomized, double-blind, placebo-controlled study of the safety and efficacy of ondansetron in the treatment of cocaine dependence. Drug Alcohol Depend 2006;84(3):256\u201363. doi: \nhttps:\/\/doi.org\/10.1016\/j.drugalcdep.2006.02.011","journal-title":"Drug Alcohol Depend"},{"issue":"10","key":"5074_CR67","doi-asserted-by":"publisher","first-page":"1861","DOI":"10.1111\/add.13868","volume":"112","author":"JM Schmitz","year":"2017","unstructured":"Schmitz JM, Green CE, Hasan KM, Vincent J, Suchting R, Weaver MF, et al. PPAR-gamma agonist pioglitazone modifies craving intensity and brain white matter integrity in patients with primary cocaine use disorder: a double-blind randomized controlled pilot trial. Addiction 2017;112(10):1861\u20138. doi: \nhttps:\/\/doi.org\/10.1111\/add.13868","journal-title":"Addiction"},{"issue":"3","key":"5074_CR68","doi-asserted-by":"publisher","first-page":"437","DOI":"10.1016\/S0306-4603(02)00226-5","volume":"28","author":"K Kampman","year":"2003","unstructured":"Kampman K, Majewska MD, Tourian K, Dackis C, Cornish J, Poole S, et al. A pilot trial of piracetam and ginkgo biloba for the treatment of cocaine dependence. Addict Behav 2003;28(3):437\u201348.","journal-title":"Addict Behav"},{"issue":"5","key":"5074_CR69","doi-asserted-by":"publisher","first-page":"453","DOI":"10.1037\/1064-1297.15.5.453","volume":"15","author":"M Sofuoglu","year":"2007","unstructured":"Sofuoglu M, Poling J, Gonzalez G, Gonsai K, Oliveto A, Kosten TR. Progesterone effects on cocaine use in male cocaine users maintained on methadone: a randomized, double-blind, pilot study. Exp Clin Psychopharmacol 2007;15(5):453\u201360. doi: \nhttps:\/\/doi.org\/10.1037\/1064-1297.15.5.453","journal-title":"Exp Clin Psychopharmacol"},{"issue":"1","key":"5074_CR70","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1016\/S0376-8716(00)00193-9","volume":"63","author":"KM Kampman","year":"2001","unstructured":"Kampman KM, Volpicelli JR, Mulvaney F, Alterman AI, Cornish J, Gariti P, et al. Effectiveness of propranolol for cocaine dependence treatment may depend on cocaine withdrawal symptom severity. Drug Alcohol Depend 2001;63(1):69\u201378.","journal-title":"Drug Alcohol Depend"},{"key":"5074_CR71","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1016\/j.drugalcdep.2016.05.019","volume":"166","author":"Y Gilgun-Sherki","year":"2016","unstructured":"Gilgun-Sherki Y, Eliaz RE, McCann DJ, Loupe PS, Eyal E, Blatt K, et al. Placebo-controlled evaluation of a bioengineered, cocaine-metabolizing fusion protein, TV-1380 (AlbuBChE), in the treatment of cocaine dependence. Drug Alcohol Depend 2016;166:13\u201320. doi: \nhttps:\/\/doi.org\/10.1016\/j.drugalcdep.2016.05.019","journal-title":"Drug Alcohol Depend"},{"issue":"5","key":"5074_CR72","doi-asserted-by":"publisher","first-page":"339","DOI":"10.1080\/00952990903108215","volume":"35","author":"X Castells","year":"2009","unstructured":"Castells X, Kosten TR, Capella D, Vidal X, Colom J, Casas M. Efficacy of opiate maintenance therapy and adjunctive interventions for opioid dependence with comorbid cocaine use disorders: A systematic review and meta-analysis of controlled clinical trials. Am J Drug Alcohol Abuse 2009;35(5):339\u201349. doi: \nhttps:\/\/doi.org\/10.1080\/00952990903108215","journal-title":"Am J Drug Alcohol Abuse"},{"key":"5074_CR73","unstructured":"Ahmad FB, Rossen LM, Spencer MR, Warner M, Sutton P. Provisional drug overdose death counts. National Center for Health Statistics. 2018. Designed by LM Rossen, A Lipphardt, FB Ahmad, JM Keralis, and Y Chong: National Center for Health Statistics. Available from \nhttps:\/\/www.cdc.gov\/nchs\/nvss\/vsrr\/drug-overdose-data.htm\n\n."},{"issue":"8","key":"5074_CR74","doi-asserted-by":"publisher","first-page":"1337","DOI":"10.1111\/add.13328","volume":"111","author":"M Singh","year":"2016","unstructured":"Singh M, Keer D, Klimas J, Wood E, Werb D. Topiramate for cocaine dependence: a systematic review and meta-analysis of randomized controlled trials. Addiction 2016;111(8):1337\u201346. doi: \nhttps:\/\/doi.org\/10.1111\/add.13328","journal-title":"Addiction"},{"issue":"3","key":"5074_CR75","doi-asserted-by":"publisher","first-page":"430","DOI":"10.2105\/ajph.2016.303627","volume":"107","author":"C McCall Jones","year":"2017","unstructured":"McCall Jones C, Baldwin GT, Compton WM. Recent Increases in Cocaine-Related Overdose Deaths and the Role of Opioids. Am J Public Health 2017;107(3):430\u20132. doi: \nhttps:\/\/doi.org\/10.2105\/ajph.2016.303627\n\n.","journal-title":"Am J Public Health"},{"issue":"5","key":"5074_CR76","doi-asserted-by":"publisher","first-page":"553","DOI":"10.3109\/10826084.2015.1122063","volume":"51","author":"RF Leeman","year":"2016","unstructured":"Leeman RF, Sun Q, Bogart D, Beseler CL, Sofuoglu M. Comparisons of Cocaine-Only, Opioid-Only, and Users of Both Substances in the National Epidemiologic Survey on Alcohol and Related Conditions (NESARC). Subst Use Misuse 2016;51(5):553\u201364. doi: \nhttps:\/\/doi.org\/10.3109\/10826084.2015.1122063\n\n.","journal-title":"Subst Use Misuse"},{"key":"5074_CR77","doi-asserted-by":"publisher","first-page":"150","DOI":"10.1016\/j.neuropharm.2014.04.002","volume":"87","author":"KA Phillips","year":"2014","unstructured":"Phillips KA, Epstein DH, Preston KL. Psychostimulant addiction treatment. Neuropharmacology. 2014;87:150-60. \nhttps:\/\/doi.org\/10.1016\/j.neuropharm.2014.04.002\n\n.","journal-title":"Neuropharmacology."},{"key":"5074_CR78","doi-asserted-by":"publisher","first-page":"CD011866","DOI":"10.1002\/14651858.CD011866.pub2","volume":"9","author":"S Minozzi","year":"2016","unstructured":"Minozzi S, Saulle R, De Crescenzo F, Amato L. Psychosocial interventions for psychostimulant misuse. Cochrane Database Syst Rev 2016;9:CD011866. doi: \nhttps:\/\/doi.org\/10.1002\/14651858.CD011866.pub2\n\n.","journal-title":"Cochrane Database Syst Rev"},{"issue":"1","key":"5074_CR79","doi-asserted-by":"publisher","first-page":"182","DOI":"10.1111\/add.13618.","volume":"112","author":"J Klimas","year":"2017","unstructured":"Klimas J, Wood E, Werb D. How can we investigate the role of topiramate in the treatment of cocaine use disorder more thoroughly? Addiction 2017;112(1):182\u20133. doi: \nhttps:\/\/doi.org\/10.1111\/add.13618.","journal-title":"Addiction"},{"issue":"8","key":"5074_CR80","doi-asserted-by":"publisher","first-page":"1347","DOI":"10.1111\/add.13369.","volume":"111","author":"S Darke","year":"2016","unstructured":"Darke S, Farrell M. Commentary on Singh et al. (2016): Still searching for the answer. Addiction 2016;111(8):1347. doi: \nhttps:\/\/doi.org\/10.1111\/add.13369.","journal-title":"Addiction"},{"key":"5074_CR81","unstructured":"Chan B, Kondo K, Ayers C, Freeman M, Montgomery J, Paynter R, et al. Pharmacotherapy for Stimulant Use Disorders: A Systematic Review of the Evidence. VA ESP Project 05\u2013225; 2018."},{"issue":"41","key":"5074_CR82","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3310\/hta7410","volume":"7","author":"D Moher","year":"2003","unstructured":"Moher D, Pham B, Lawson ML, Klassen TP. The inclusion of reports of randomised trials published in languages other than English in systematic reviews. Health Technol Assess 2003;7(41):1\u201390","journal-title":"Health Technol Assess"},{"issue":"11","key":"5074_CR83","doi-asserted-by":"publisher","first-page":"1269","DOI":"10.1176\/appi.ajp.2009.08121811","volume":"166","author":"JD Brodie","year":"2009","unstructured":"Brodie JD, Case BG, Figueroa E, Dewey SL, Robinson JA, Wanderling JA, et al. Randomized, double-blind, placebo-controlled trial of vigabatrin for the treatment of cocaine dependence in Mexican parolees. Am J Psychiatry 2009;166(11):1269\u201377. doi: \nhttps:\/\/doi.org\/10.1176\/appi.ajp.2009.08121811","journal-title":"Am J Psychiatry"},{"issue":"6","key":"5074_CR84","doi-asserted-by":"publisher","first-page":"630","DOI":"10.1001\/jamapsychiatry.2013.872","volume":"70","author":"EC Somoza","year":"2013","unstructured":"Somoza EC, Winship D, Gorodetzky CW, Lewis D, Ciraulo DA, Galloway GP, et al. A multisite, double-blind, placebo-controlled clinical trial to evaluate the safety and efficacy of vigabatrin for treating cocaine dependence. JAMA Psychiatry 2013;70(6):630\u20137. doi: \nhttps:\/\/doi.org\/10.1001\/jamapsychiatry.2013.872","journal-title":"JAMA Psychiatry"},{"issue":"12","key":"5074_CR85","doi-asserted-by":"publisher","first-page":"1080","DOI":"10.1016\/S0006-3223(99)00310-8","volume":"47","author":"TP George","year":"2000","unstructured":"George TP, Chawarski MC, Pakes J, Carroll KM, Kosten TR, Schottenfeld RS. Disulfiram versus placebo for cocaine dependence in buprenorphine-maintained subjects: a preliminary trial. Biol Psychiatry 2000;47(12):1080\u20136.","journal-title":"Biol Psychiatry"},{"issue":"2","key":"5074_CR86","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1046\/j.1360-0443.2000.9522198.x","volume":"95","author":"IL Petrakis","year":"2000","unstructured":"Petrakis IL, Carroll KM, Nich C, Gordon LT, McCance-Katz EF, Frankforter T, et al. Disulfiram treatment for cocaine dependence in methadone-maintained opioid addicts. Addiction 2000;95(2):219\u201328.","journal-title":"Addiction"}],"container-title":["Journal of General Internal Medicine"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11606-019-05074-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s11606-019-05074-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11606-019-05074-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,6,9]],"date-time":"2020-06-09T20:05:16Z","timestamp":1591733116000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s11606-019-05074-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,6,10]]},"references-count":86,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2019,12]]}},"alternative-id":["5074"],"URL":"https:\/\/doi.org\/10.1007\/s11606-019-05074-8","relation":{},"ISSN":["0884-8734","1525-1497"],"issn-type":[{"value":"0884-8734","type":"print"},{"value":"1525-1497","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,6,10]]},"assertion":[{"value":"29 April 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 May 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 June 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with Ethical Standards"}},{"value":"The authors declare that they do not have a conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"The findings and conclusions in this document are those of the authors who are responsible for its contents; the findings and conclusions do not necessarily represent the views of the Department of Veterans Affairs or the US government.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Disclaimer"}},{"value":"This content has been made available to all.","name":"free","label":"Free to read"}]}}